Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Income from Continuing Operations of 48823000.0 for Q1 2026, down 11.61% sequentially from 43746000.0 in Q4 2025, and up 23.14% YoY from 39647583.92 in Q1 2025.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Income from Continuing Operations for 13 years, with the latest figure at 48823000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 23.14% year-over-year to 48823000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 310003000.0 (down 16.75% YoY) and the FY2025 annual result came in at 361614000.0, up 8.22% from the prior year.
- Income from Continuing Operations declined to 48823000.0 in Q1 2026 per RCKT's latest filing, from 43746000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 43746000.0 in Q4 2025 and troughed at 190825000.0 in Q3 2023.
- A 5-year average of 100417235.29 and a median of 71889000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 67.35% in 2022, then tumbled 64.86% in 2025.
- Over 5 years, Income from Continuing Operations stood at 68304000.0 in 2022, then gained by 7.86% to 62935000.0 in 2023, then gained by 2.2% to 61550000.0 in 2024, then gained by 28.93% to 43746000.0 in 2025, then declined by 11.61% to 48823000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 48823000.0, 43746000.0, and 98921000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | 123.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 123.21 Mn |
| Mar 31, 2026 | -48.82 Mn |
| Dec 31, 2025 | -43.75 Mn |
| Sep 30, 2025 | -52.01 Mn |
| Jun 30, 2025 | -68.92 Mn |
| Mar 31, 2025 | -63.52 Mn |
| Dec 31, 2024 | -61.55 Mn |
| Sep 30, 2024 | -68.57 Mn |
| Jun 30, 2024 | -71.89 Mn |
| Mar 31, 2024 | -64.82 Mn |
| Dec 31, 2023 | -62.94 Mn |
| Sep 30, 2023 | -64.18 Mn |
| Jun 30, 2023 | -68.38 Mn |
| Mar 31, 2023 | -60.75 Mn |
| Dec 31, 2022 | -68.30 Mn |
| Sep 30, 2022 | -57.60 Mn |
| Jun 30, 2022 | -54.01 Mn |
| Mar 31, 2022 | -42.41 Mn |
| Dec 31, 2021 | -43.95 Mn |
| Sep 30, 2021 | -49.37 Mn |